Cortical neuroanatomic correlates of symptom severity in primary progressive aphasia

ABSTRACT

Objective: To test the validity and reliability of a new measure of clinical impairment in primary progressive aphasia (PPA), the Progressive Aphasia Severity Scale (PASS), and to investigate relationships with MRI-based cortical thickness biomarkers for localizing and quantifying the severity of anatomic abnormalities.

Methods: Patients with PPA were rated using the PASS and underwent performance-based language testing and MRI scans that were processed for cortical thickness measures.

Results: The level of impairment in PASS fluency, syntax/grammar, and word comprehension showed strong specific correlations with performance-based measures of these domains of language, and demonstrated high interrater reliability. Left inferior frontal thinning correlated with impairment in fluency and grammar/syntax, while left temporopolar thinning correlated with impairment in word comprehension. Discriminant function analysis demonstrated that a combination of left inferior frontal, left temporopolar, and left superior temporal sulcal thickness separated the 3 PPA subtypes from each other with 100% accuracy (87% accuracy in a leave-one-out analysis).

Conclusions: The PASS, a novel measure of the severity of clinical impairment within domains of language typically affected in PPA, demonstrates reliable and valid clinical-behavioral properties. Furthermore, the presence of impairment in individual PASS domains demonstrates specific relationships with focal abnormalities in particular brain regions and the severity of impairment is strongly related to the severity of anatomic abnormality within the relevant brain region. These anatomic imaging biomarkers perform well in classifying PPA subtypes. These data provide robust support for the value of this novel clinical measure and the new imaging measure as markers for potential use in clinical research and trials in PPA. Neurology® 2010;75:358–366

GLOSSARY

AD = Alzheimer disease; BDAE = Boston Diagnostic Aphasia Examination; CDR = Clinical Dementia Rating; CSB = Cambridge Semantic Battery; ICC = intraclass correlation coefficient; NACC UDS = National Alzheimer's Coordinating Center Uniform Data Set; OC = older control participants; PASS = Progressive Aphasia Severity Scale; PPA = primary progressive aphasia; PPA-G =agrammatic primary progressive aphasia; PPA-L = logopenic primary progressive aphasia; PPA-S = semantic primary progressive aphasia; ROI = region of interest; WAB = Western Aphasia Battery.

Planning clinical trials for primary progressive aphasia (PPA)¹ is challenging, in part because of clinicopathologic heterogeneity²³ and in part because of a paucity of clinical assessment instruments specifically tailored to this population.⁴ Although quantitative performance-based linguistic measures are valuable,⁵ research in Alzheimer disease (AD) has demonstrated that performance-based measures provide only one facet of the clinical picture, while clinician judgment–based ratings of symptom severity provide complementary information that is useful in grading illness severity and prognostication.⁶ The Clinical Dementia Rating (CDR) scale⁷ is such an instrument of widely acknowledged utility in AD clinical research and trials.
At present, PPA symptom rating instruments are lacking—language ratings are not part of the original CDR, and the new language supplement in the National Alzheimer’s Coordinating Center Uniform Data Set (NACC UDS) is a single global rating that captures overall level of language impairment but does not differentiate specific language domains. Since the predominant domain of language impairment relates to the localization of atrophy/hypometabolism and this localization appears to relate probabilistically to molecular neuropathology, it would likely be of value for both clinical and pathologic investigations to develop additional methods for quantifying impairment in different language domains.

Building on the CDR supplemental language box, we developed and piloted an approach to the rating of symptoms in 3 language domains that have traditionally been employed in PPA clinical characterization—speech fluency, syntax and grammar, and single word comprehension. We also investigated the anatomic correlates of impairment in these domains. These data were then analyzed to determine how well the measures perform in diagnostic sensitivity and specificity. The overall goal of these efforts was to determine whether anatomic measures are a sensitive and specific reflection of the presence and severity of various types of language impairment in PPA, with the aim of using both of these kinds of measures in PPA clinical research and trials.

METHODS Participants, clinical assessment, and MRI data acquisition. Forty right-handed participants were studied. Patients with PPA (n = 23) were recruited from an ongoing longitudinal study being conducted in the Progressive Aphasia Program in the Massachusetts General Hospital Frontotemporal Dementia Unit, and were evaluated using a structured clinical assessment performed by a behavioral neurologist (B.C.D.) and speech and language pathologist (D.S.). The clinical evaluation of each patient by the neurologist included 1) behavioral observations of the patient’s speech and language during a semi-structured interview regarding history of illness; 2) speech-language examination, which included structured conversation (e.g., “What did you do for work?” “How do you spend your weekends?”), picture descriptions, and a brief language assessment similar to that of the Addenbrooke’s Cognitive Examination including tasks of naming, repetition, word comprehension, and a motor speech examination; and 3) history from informant.

In addition, elements of the WAB, BDAE, and CSB were performed as part of the speech pathologist’s evaluation; these quantitative measures were not used in generating Progressive Aphasia Severity Scale (PASS) ratings (see below). The diagnosis of PPA was made if 1) a gradually progressive language disturbance was the most salient symptom prompting the patient/family to seek clinical evaluation; 2) the progressive nature of the deficits and the fact that the language disorder was the chief problem during the initial few years of the disease were documented by the history obtained from the patient and an informant who knows the patient well; and 3) the presence of aphasia was documented by a structured clinical evaluation which also demonstrated the absence of other salient deficits. PPA subtypes (agrammatic [PPA-G], semantic [PPA-S], logopenic [PPA-L], and mixed/other) were diagnosed using an approach similar to that previously described.

In addition, older control participants (OC, n = 17; mean age = 70.6 years, SD = 9; 11 female) were included for MRI analyses. As participants in the Massachusetts Alzheimer’s Disease Research Center Longitudinal Cohort, they undergo a comprehensive annual evaluation by experienced clinicians and were selected for this analysis based on a normal clinical status (CDR = 0).

In this sample, MRI data were acquired using a Siemens Trio 3.0 Tesla scanner (Siemens Medical Systems, Erlangen, Germany). Procedures for data collection included head movement restriction using expandable foam cushions and automated scout and shimming procedures. Two 3-dimensional magnetization-prepared rapid gradient echo sequences were acquired (repetition time/inversion time/echo time 2,300/900/2.98 msec, field of view 256, flip angle 7°, 192 sagittal 1-mm-thick slices, matrix 240 × 256). A fluid-attenuated inversion recovery sequence was visually inspected to rule out nondegenerative pathologies.

Standard protocol approvals, registrations, and patient consents. All participants gave written informed consent in accordance with guidelines established by the Partners Human Research Committee.

Progressive Aphasia Severity Scale. The PASS is a structured clinical instrument, currently under development and modeled after the CDR scale, that aims to provide a semi-quantitative grading of the severity of impairment within a variety of speech and language domains. This 5-point scale enables the clinician to capture change from the patient’s premorbid baseline. Ratings are made from normal (0) to questionable/very mild (0.5), mild (1.0), moderate (2.0), or severe (3.0) impairment.

The version of the PASS described here is meant to provide an initial elaboration upon the Supplementary Language Box currently in use in the NACC UDS 2.0, which provides a single global rating of language impairment. Based on the hallmark features of progressive aphasia, the first 3 domains of language for which ratings have been developed are fluency of speech, syntax and grammar, and single word comprehension. Scoring criteria are provided in table 1.
### Table 1

<table>
<thead>
<tr>
<th>Abbreviated Progressive Aphasia Severity Scale, version 5.1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Questionable/very mild</strong></td>
</tr>
<tr>
<td>Speech contains occasional blank spaces but speech flows easily or is interrupted by hesitations, fillers, pauses, or morphology markers.</td>
</tr>
<tr>
<td>Occasional difficulty understanding low-frequency or familiar words; questions the meaning of words (e.g., “What is a — — —?”).</td>
</tr>
<tr>
<td>Minimal comprehension of single words (e.g., cork); may question it is effortful to combine words to form phrases and sentences.</td>
</tr>
<tr>
<td>Syntax and grammar: use of words (e.g., run, ran), other function words (the, an), and word order when forming phrases and sentences in speech or writing.</td>
</tr>
<tr>
<td>Single-word comprehension; reading and writing of single words.</td>
</tr>
<tr>
<td>No difficulty in the use of grammar and syntax.</td>
</tr>
<tr>
<td>Ongoing comprehension when sentence length rarely exceeds 3 words.</td>
</tr>
<tr>
<td>Speech in short phrases, interrupted there are occasional runs of fluent speech.</td>
</tr>
<tr>
<td>Utterances contain mostly content words, groups, or morphologic markers.</td>
</tr>
<tr>
<td>Slight agrammatism or paragrammatism (i.e., odd sentence structure such as, “I my run”).</td>
</tr>
<tr>
<td>No difficulty understanding single words in conversation or testing.</td>
</tr>
<tr>
<td>minimal proficiency in spoken language.</td>
</tr>
<tr>
<td>Normal flow of speech.</td>
</tr>
<tr>
<td>Normal (0)</td>
</tr>
<tr>
<td>Impairment (0.5)</td>
</tr>
<tr>
<td>Mild impairment (1)</td>
</tr>
<tr>
<td>Moderate impairment (2)</td>
</tr>
<tr>
<td>Severe impairment (3)</td>
</tr>
</tbody>
</table>

**Abbreviation:** WPM = words per minute.
RESULTS  Word-finding difficulty was reported as the presenting symptom in about half the participants. Other presenting symptoms included slurring or mispronunciation of words or stuttering or false starts (often phonologic errors on examination), problems using grammar, confusion about word meanings, difficulty understanding idioms, or difficulty reading. Subtype diagnoses included PPA-G, PPA-S, and PPA-L variants. Demographic and clinical characteristics are presented in table 1. Despite deficits in confrontation naming, all patients with PPA-L demonstrated substantial improvements with phonemic cueing or 3-choice recognition, indicating intact semantic knowledge of word meaning.

PASS characteristics. Interrater reliability (between neurologist and speech pathologist) of PASS ratings was high, with ICC >0.9 for fluency (0.99), grammar/syntax (0.99), word comprehension (0.91), and global CDR language (1.0). For subsequent analyses, we use a consensus PASS score of the 2 raters. The degree of impairment reflected by PASS scores was closely related to specific performance deficits, supporting the validity of the scale (table 2). Correlations were present between PASS fluency and WAB fluency ($r = -0.92$) and BDAE grammar ($r = -0.94$), PASS syntax/grammar and WAB fluency ($r = -0.81$) and BDAE grammar ($r = -0.82$), and PASS word comprehension and CSB word-picture matching ($r = -0.87$). The NACC UDS Global Language measure correlated with WAB fluency ($r = -0.59$) and BDAE grammar ($r = -0.66$) but not CSB.

The fluency and grammar/syntax measures for patients in this study were correlated ($r = 0.76$), but word comprehension was not correlated with fluency or grammar/syntax ($p > 0.3$).

Anatomic findings related to symptom severity. Hypothesis-driven analyses demonstrated that left inferior frontal cortical thickness correlated with severity of impairment in fluency ($r = -0.71$) and grammar/syntax domains ($r = -0.57$) but these clinical measures did not correlate with temporal polar thickness (figure 1). Severity of impairment in the comprehension domain correlated with left temporopolar cortical thickness ($r = -0.68$) but not inferior frontal thickness. The CDR global language rating was not correlated with either ROI ($p > 0.1$).

Exploratory maps across the entire cortex focusing on specific symptoms revealed that grammar/syntax was most strongly correlated with thickness in caudal inferior and middle frontal regions, with strong but not complete left lateralization (figure e-1A on the Neurology® Web site at www.neurology.org). Since the fluency measure was correlated with the grammar/syntax measure, the exploratory map looks very similar. Comprehension was most strongly correlated with temporopolar thickness (figure e-1B).

Finally, exploratory maps comparing each of the 3 PPA subtypes to controls demonstrated strongly left-lateralized inferior, middle, and superior frontal, pre-central, and caudal superior temporal sulcal thinning in PPA-G, strongly left-lateralized superior and middle temporal and inferior parietal sulcal thinning in PPA-L, and left-lateralized temporal pole thinning in PPA-S (figure 2).

Diagnostic classification. A stepwise discriminant function analysis aiming to separate PPA subtypes from each other was performed using the a priori ROIs in this study—left inferior frontal gyrus and left temporal pole—as well as 2 ROIs defined in the logopenic subtype in this study—left superior temporal sulcus and left supramarginal gyrus. This stepwise analysis demonstrated that a combination of the left temporal pole, left superior temporal sulcus, and the left inferior frontal gyrus was best at discriminating the 3 PPA subtypes from each other ($\chi^2 = 18.2$, $p < 0.01$), with an accuracy of 100%. Leave-one-out analysis demonstrated an accuracy of 87% (100% PPA-S, 89% PPA-G [1 patient classified as logopenic], and 66% of PPA-L [1 patient classified as semantic and 1 as agrammatic]; figure 3).

DISCUSSION Impairments in patients with PPA are heterogeneous, and quantification is essential for monitoring and the ultimate evaluation of potential treatments. PPA impairments are typically quantified using language test performance measures. Here we have extended recent work to quantify the overall impairment of language functions through the judgment of trained clinicians, an approach that has traditionally played an important role in AD clinical research and trials. We developed a method for clinician judgment-based grading of overall impairment in fluency, grammar/syntax, and single word comprehension, since these are hallmark language abnormalities in PPA and are often dissociated from each other. The present study demonstrated that this approach is reliable between raters and is valid against performance-based measures. Since performance-based and clinician-rated measures of cognitive impairment are not completely redundant in AD, it stands to reason that they may provide complementary information in PPA, although this deserves further study. Furthermore, the clinician-graded impairments in fluency/grammar/syntax and comprehension are strongly dissociated with respect to neuroanatomic abnormalities in cortical thickness,
<table>
<thead>
<tr>
<th>Patient</th>
<th>PPA subtype</th>
<th>Age, y</th>
<th>Gender</th>
<th>Education, y</th>
<th>Symptom duration, y</th>
<th>CDR global</th>
<th>CDR supplemental–behavior</th>
<th>CDR supplemental–language</th>
<th>BDAE Aphasia Severity Rating Scale</th>
<th>Naming</th>
<th>Speech fluency, grammar, and syntax</th>
<th>Auditory comprehension</th>
<th>PASS rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PPA-S</td>
<td>59</td>
<td>M</td>
<td>16</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>NT</td>
<td>8</td>
<td>NT</td>
<td>0.5</td>
</tr>
<tr>
<td>2</td>
<td>PPA-S</td>
<td>68</td>
<td>M</td>
<td>18</td>
<td>13</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>NT</td>
<td>6</td>
<td>NT</td>
<td>0.5</td>
</tr>
<tr>
<td>3</td>
<td>PPA-G</td>
<td>58</td>
<td>M</td>
<td>12</td>
<td>6</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>NT</td>
<td>10</td>
<td>NT</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>PPA-G</td>
<td>70</td>
<td>M</td>
<td>16</td>
<td>8</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>5</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>PPA-G</td>
<td>61</td>
<td>F</td>
<td>14</td>
<td>6</td>
<td>0.5</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>PPA-G</td>
<td>60</td>
<td>F</td>
<td>15</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>PPA-G</td>
<td>64</td>
<td>F</td>
<td>19</td>
<td>2</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>PPA-G</td>
<td>50</td>
<td>M</td>
<td>20</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>PPA-G</td>
<td>79</td>
<td>M</td>
<td>16</td>
<td>5</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>PPA-G</td>
<td>68</td>
<td>M</td>
<td>20</td>
<td>6</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>11</td>
<td>PPA-G</td>
<td>60</td>
<td>M</td>
<td>12</td>
<td>5</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>PPA-G</td>
<td>59</td>
<td>F</td>
<td>16</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>PPA-G</td>
<td>76</td>
<td>M</td>
<td>18</td>
<td>4</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>PPA-G</td>
<td>70</td>
<td>M</td>
<td>20</td>
<td>4</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>PPA-G</td>
<td>53</td>
<td>M</td>
<td>16</td>
<td>5</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td>PPA-G</td>
<td>68</td>
<td>M</td>
<td>16</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>17</td>
<td>PPA-G</td>
<td>70</td>
<td>M</td>
<td>16</td>
<td>4</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>18</td>
<td>PPA-G</td>
<td>60</td>
<td>M</td>
<td>18</td>
<td>5</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>19</td>
<td>PPA-G</td>
<td>70</td>
<td>M</td>
<td>18</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>PPA-G</td>
<td>65</td>
<td>M</td>
<td>16</td>
<td>4</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>21</td>
<td>PPA-G</td>
<td>70</td>
<td>M</td>
<td>18</td>
<td>5</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>22</td>
<td>PPA-G</td>
<td>60</td>
<td>M</td>
<td>18</td>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
<tr>
<td>23</td>
<td>PPA-G</td>
<td>65</td>
<td>M</td>
<td>16</td>
<td>4</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>NT</td>
<td>4</td>
<td>NT</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: BDAE = Boston Diagnostic Aphasia Examination-3; CDR = Clinical Dementia Rating; CSB = Cambridge Semantic Battery; N/A = not available; NT = not tested; PASS = Progressive Aphasia Severity Scale; PPA = primary progressive aphasia; PPA-G = agrammatic primary progressive aphasia; PPA-L = logopenic primary progressive aphasia; PPA-S = semantic primary progressive aphasia; WAB = Western Aphasia Battery–revised.

* Naming: CSB except where indicated by * to indicate Boston Naming Test.
* Scores were determined by applying the scale to available speech and language samples, which did not always include those from the BDAE and WAB tasks.
* BDAE grammatical form scale rating descriptions: 1 = no syntactic word groupings; 4 = simplified or incomplete forms; omissions of required grammatical morphemes; 7 = normal range of syntax; normal facility with grammatical words.
* Following commands: *BDAE Commands task; WAB Sequential task.
also supporting their validity. Both hypothesis-driven and exploratory analyses demonstrated sensitive and specific relationships between impaired syntax/grammar and ventrolateral prefrontal atrophy, and between impaired word comprehension and temporopolar atrophy.

We have previously shown through longitudinal clinical research in prodromal AD that measures grading both symptom severity in daily life and in the office and performance abilities on psychometric testing can provide complementary information with respect to present level of impairment as well as prognosis. Every clinician has worked with a patient who exhibits prominent symptoms in daily life yet who performs relatively well on office-based tests. Conversely, there are many patients who have relatively subtle symptoms, maintaining generally good function in complex activities of daily life, yet who perform strikingly poorly on tests. This can be particularly true in some patients with fluent, word comprehension-centered forms of PPA. Thus, we believe it is critical for the field to continue to develop and apply a rich set of instruments for clinical assessment, ideally tailored to the PPA population and including patient- and informant-rated questionnaires, performance-based instruments, and clinician-graded measures. A comprehensive battery of such measures will likely be of great value for clinical research and ultimately treatment trials. We hope that the PASS instrument described here is of use for that goal, and that the specific anatomic relationships found here provide data to support its validity.

Previous studies of PPA have demonstrated the relationships between semantic deficits and left temporopolar atrophy as well as deficits in syntactic processing and inferior frontal atrophy. Yet there have been few investigations of these dissociable relationships within a single sample of patients with PPA. The investigation of dissociated deficits in

Figure 1  Hypothesis-driven analysis of the relationship between specific regions of interest (ROIs) and the severity of specific symptoms

(A) A priori anatomically defined caudal left inferior frontal gyrus (LIFG) ROI and left temporopolar (LTP) ROI were used in this analysis. (B) Correlation between LIFG ROI thickness and grammatical/syntactic impairment ($r = -0.71, p < 0.005$). (C) Correlation between LTP ROI thickness and word comprehension impairment ($r = -0.68, p < 0.003$). PASS = Progressive Aphasia Severity Scale.
single samples of patients with PPA has revealed valuable findings regarding some aspects of language dysfunction in PPA, particularly naming deficits with temporopolar atrophy and nonfluent/agrammatic speech with middle and inferior frontal atrophy. A recent study employed cortical thickness analysis in comparison with performance-based measures of grammar and semantic processing and found that the patterns of localization of cortical thinning for the 3 subtypes were remarkably similar to those identified here. Notably, the caudal middle temporal gyrus/superior temporal sulcus—a critical region for linking speech sounds to word meaning—is involved in all 3 variants. Another recent study employing cortical thickness analysis showed a similar pattern of thinning for the PPA-semantic subtype but a somewhat different pattern for PPA-nonfluent subtype, raising questions about whether that sample was truly clinically comparable to the present one. One advantage of cortical thickness analysis in this type of work is that the measures can be obtained from single individuals using an a priori ROI approach, and cortical thickness measures are directly related to morphometric measures that can be made.

**Figure 2** Regionally specific cortical thinning in primary progressive aphasia (PPA) subtypes

Exploratory analyses of the localization of cortical thinning in (A) PPA-agrammatic patients compared to controls, (B) PPA-semantic patients compared to controls, and (C) PPA-logopenic patients compared to controls. The color scale at the bottom represents the p value of the effects (p < 0.01).

**Figure 3** Anatomic measures can accurately discriminate primary progressive aphasia (PPA) subtypes

Discriminant plot of each PPA participant in this study as a function of (A) left temporopolar thickness (y axis) and left superior temporal thickness (x axis) and (B) left inferior frontal thickness (y axis) and left superior temporal thickness (x axis). The use of these 3 anatomic measures can accurately separate PPA-semantic variant patients (squares) from PPA-agrammatic variant patients (circles) from PPA-logopenic variant patients (triangles). Lines are drawn to approximate the discriminability matrix but actual discriminant functions are more complex.
in postmortem brain specimens. Although the cellular and pathologic correlates of cortical thickness have received little study, some histologic data indicate that cortical thinning is present in regions that harbor AD pathology. Yet while regional cortical thinning identified via in vivo MRI measures in patients with presumed neurodegenerative syndromes is undoubtedly valuable in localizing pathologic change, it seems much less likely that these regional measures will provide specific evidence regarding the molecular nature of that pathology.

The congruence between the anatomic classification of patients with PPA using inferior frontal, temporopolar, and superior temporal sulcal thickness and clinical subtyping is impressively good (figure 3), as has similarly been demonstrated using atrophy pattern classification analyses. Such findings suggest that these types of quantitative MRI-based measures deserve a place in new clinical diagnostic criteria since they can be applied at the individual level, similarly to recently reported performance-based measures. Limitations of the present study include the lack of additional domains in the PASS rating scale. It is clear that patients with PPA can exhibit a variety of other relevant symptoms beyond impaired fluency, grammar/syntax, and comprehension. Fluency can be impaired for a variety of reasons (such as impairments in grammar/syntax, phonology, or word retrieval), so this measure may ultimately need to be refined or replaced, but it is useful at present. We have developed ratings for other domains of language function, including word retrieval, repetition, articulation, and others, and are currently testing these measures (the current scale is available upon request). It is also not clear how readily the PASS approach used here will generalize within the community of PPA investigators, but studies are being planned to evaluate its performance at multiple centers. It is not clear how well the PASS will perform in differentiating types of impairment in patients with more advanced stages of illness; it seems to perform very well in mildly to moderately impaired patients. Finally, we do not yet know how well the clinical or anatomic measures employed here will perform in longitudinal analyses, but these investigations are underway. Ultimately, we hope that further investigation will demonstrate that the types of measures studied here can be translated into clinical and imaging markers for use in diagnosis, monitoring, and prognostication, and will prove useful in clinical trials of novel therapeutics for these devastating diseases.

AUTHOR CONTRIBUTIONS
Statistical analysis was conducted by Dr. B.C. Dickerson.

ACKNOWLEDGMENT
The authors thank the faculty and staff of the Massachusetts ADRC and the MGH Cognitive and Behavioral Neurology Unit, the MGH Speech and Language Pathology Department, MGH Psychology Assessment Center, the Division of Cognitive and Behavioral Neurology at Brigham and Women’s Hospital, the Beth Israel Behavioral Neurology Unit, the Harold Goodglass Aphasia Research Center, and other providers who referred patients. The authors thank the staff at the Martinos Center for Biomedical Imaging, particularly Mary Foley and Larry White, for their technical expertise, and the staff of the MGH ADRC for their expertise in coordinating and evaluating participants in the Longitudinal Cohort. The authors also thank the participants in this study and their families for their contributions.

DISCLOSURE
D. Sapolsky, A. Bakkour, A. Negreira, and P. Nalipinski report no disclosures. Dr. Weintraub serves on the editorial boards of Alzheimer’s and Dementia, the Turkish Journal of Neurology, and Dementia & Neuropsychologia and receives research support from the NIH (NIA NS1P30 AG13854-06 [Co-I, Clinical Core Leader], NIA 1 T32 AG20506-01-05 [Associate Director], NIDCD KO8 DC01755-01 [Mentor], and NIDCD AG-266-06-01 [Co-I]). Dr. Mesulam serves on scientific advisory boards for the Cure Alzheimer Fund and the Association on Fronotemporal Dementia; serves on the editorial boards of Brain, Annals of Neurology, Human Brain Mapping, and the Journal of Cognitive Neuroscience; receives royalties from the publication of Principles of Behavioral and Cognitive Neuroscience (Oxford University Press, 2000); and receives research support from the NIH (AG13854 [PI] and DC00852 [PI]). Dr. Caplan serves on the editorial board of Language and Cognitive Processes and receives research support from the NIH (5 R01 DC00942-12 [PI], NIDCD 5 R01 DC02145-12 [PI], NIDCD 1R21DC010461-01 [PI of MGH subcontract], NIDCD 2 R01 DC003518-11A1 [Investigator], R350G508003 [Investigator], 1R01DC01130-01 [PI], R01 MH087569 [Investigator], 1R01AG033583-01A2 [Co-I], and R350G508003 [Investigator]). Dr. Dickerson serves on the editorial board of Hippocampus and receives research support from the NIH (R01 AG29411 [PI] and R21 AG29840 [PI]) and from the Alzheimer’s Association.

Received December 21, 2009. Accepted in final form April 8, 2010.

REFERENCES
28. Weintraub S, Mesulam M. With or without FUS, it is the anatomy that dictates the dementia phenotype. Brain 2009;132:2906–2908.
Cortical neuroanatomic correlates of symptom severity in primary progressive aphasia

D. Sapolsky, A. Bakkour, A. Negreira, P. Nalipinski, S. Weintraub, M.-M. Mesulam, D. Caplan and B.C. Dickerson

Neurology 2010;75;358-366
DOI: 10.1212/WNL.0b013e3181ea15e8

This information is current as of July 27, 2010

Updated Information & Services
including high-resolution figures, can be found at:
http://www.neurology.org/cgi/content/full/75/4/358

Supplementary Material
Supplementary material can be found at:
http://www.neurology.org/cgi/content/full/75/4/358/DC1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
MRI
http://www.neurology.org/cgi/collection/mri
Volumetric MRI
http://www.neurology.org/cgi/collection/volumetric_mri
Aphasia
http://www.neurology.org/cgi/collection/aphasia
Frontotemporal dementia
http://www.neurology.org/cgi/collection/frontotemporal_dementia
Dementia aphasia
http://www.neurology.org/cgi/collection/dementia_aphasia

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/misc/Permissions.shtml

Reprints
Information about ordering reprints can be found online:
http://www.neurology.org/misc/reprints.shtml